Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 15 October 2024

Overview

The Therapeutic Goods Act 1989, enacted to regulate the supply of therapeutic goods in Australia, was introduced to address the need for ensuring the quality, safety, and efficacy of therapeutic products available to consumers. The Act empowers the Therapeutic Goods Administration (TGA) to grant licences to manufacturers, ensuring that only those who meet stringent regulatory standards can produce therapeutic goods. This legislation was enacted by the Parliament of Australia to fill the legislative gap in overseeing the manufacture of therapeutic goods, thereby protecting public health by ensuring that only safe and effective products reach the market. The policy objective of the Therapeutic Goods Act 1989 is to safeguard the health and safety of the Australian public by regulating the supply of therapeutic goods, including prescription medicines, medical devices, and blood products, through a licensing framework that mandates compliance with quality and safety standards.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health and Aged Care, governs the regulation of therapeutic goods in Australia. This Act applies to entities that manufacture, import, supply, or advertise therapeutic goods, which include medicines, medical devices, blood, and tissues. The scope of this legislation covers a broad range of industries and activities, ensuring that all therapeutic goods meet required safety, quality, and efficacy standards before they are made available to the public. The Act applies across the Commonwealth, with uniform standards enforced to protect public health and safety nationwide. The Act does not, however, apply to therapeutic goods that are exempt under Section 41A of the Act, which includes certain low-risk products such as certain over-the-counter medicines and complementary medicines. The application and enforcement of the Act may be extended or restricted by subordinate instruments, such as regulations and guidelines, which provide further detail on specific requirements and standards for different types of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, mandates that the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, must grant licences to entities for the manufacture of therapeutic goods. The recent publication (Gazette, 15 October 2024) includes details on the licence granted to three companies: Pharmaceutical Packaging Professionals Pty Ltd trading as PCI Pharma Services, Toll Transport Pty Ltd, and Flourish Pharmaceuticals Australia Pty Ltd. Each of these companies has been issued a specific licence number and address, signifying their approval to manufacture therapeutic goods. The Act imposes certain obligations and requirements on these licence holders. Firstly, they must adhere to stringent quality control measures to ensure that the therapeutic goods they produce meet the safety, efficacy, and quality standards set by the Therapeutic Goods Administration. This includes maintaining thorough documentation and records of their manufacturing processes, which are subject to inspection and audit by the Administration. Additionally, any changes to the manufacturing processes, facilities, or products must be reported and approved by the Administration before implementation. Breach of the requirements stipulated in the Therapeutic Goods Act 1989 can lead to serious consequences. Offences under the Act may result in substantial fines, imprisonment, or both, depending on the severity and intent of the breach. For instance, knowingly manufacturing or supplying therapeutic goods that do not meet the required standards can lead to penalties that include fines of up to $2,200,000 for corporations and lesser amounts for individuals, along with potential imprisonment for up to 10 years. Civil actions may also be pursued by affected parties seeking compensation for harm caused by non-compliance with the Act. It is imperative for licence holders to strictly comply with the Act to avoid these severe penalties and maintain their standing in the industry.